)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AstraZeneca
AstraZeneca (AZN) investor relations material
AstraZeneca Investor update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor update summary26 Oct, 2026
Congress highlights
ESMO and WCLC 2026 drew >140 abstract acceptances and >110 posters; ESMO featured four Presidential datasets and 38 oral presentations across 27 approved and potential medicines and >15 tumour types.
Two Phase III datasets were described as practice-changing, alongside early data for the 2030+ pipeline.
Bladder cancer: VOLGA
In cisplatin-ineligible or cisplatin-refusing MIBC, perioperative Imfinzi plus three neoadjuvant cycles of enfortumab vedotin improved EFS vs control (HR 0.51; median not reached vs 12.1 months) and OS (HR 0.58; median not reached in either arm).
At 23 months’ median follow-up, 2-year survival was 78%; pathological complete response was 45% vs 10%, and ctDNA clearance was 60% among baseline ctDNA-positive evaluable patients.
Grade 3/4 adverse events occurred in 30%; safety was consistent with known agent profiles, surgery was not compromised, and quality of life was maintained after surgery.
The regimen was positioned as a potential new standard and an attractive finite-course alternative; practice and reimbursement may shape uptake versus EV-pembrolizumab.
In the third VOLGA arm, adding tremelimumab produced EFS and OS HRs of 0.61 and 0.77; greater immune toxicity and lower enfortumab vedotin intensity may have limited activity.
Lung cancer
SAFFRON in post-TKI advanced NSCLC with MET overexpression and/or amplification improved median PFS to 7.6 vs 5.4 months (HR 0.55) and OS to 17.8 vs 12.9 months (HR 0.68) vs platinum-pemetrexed.
In China-only first-line SANOVO, Tagrisso plus savolitinib improved investigator-assessed PFS in the ITT population to 24.9 vs 13.8 months (HR 0.56); in MET IHC 3+ patients, median PFS was 24.5 vs 11.3 months.
SANOVO OS HR was 0.48, with median OS of 44.5 vs 34.9 months; combination safety was consistent with established profiles.
In ES-SCLC without progression after first-line chemotherapy plus Imfinzi, adding Imdelltra improved median OS to 21.1 vs 12.7 months (HR 0.42) and PFS to 7.4 vs 1.9 months (HR 0.34).
DeLLphi-305 benefit extended across predefined subgroups, including patients with brain or liver metastases; safety was manageable, with infrequent discontinuations and no treatment-related fatalities in the combination arm.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AstraZeneca
- FY 2023 revenue rose 6% and Core EPS 15%, with FY 2024 double-digit growth guided.AZN
Q4 2023 - HICKORY missed its primary endpoint; efzimfotase alfa retains $3B–$5B peak-sales potential.AZNAZN Meet The Management at ASBMR 2026
- Tozorakimab reduced COPD exacerbations by up to 34% in Phase III, supporting major growth targets.AZNInvestor update
- H1 2026 revenue up 6% CER, Core EPS up 11%, driven by Oncology and Rare Disease growth.AZNQ2 2026
- Ambitious 2030 targets drive emissions cuts, health equity, and innovation in sustainability.AZNInvestor update
- Q1 2026 saw 13% revenue growth, strong Oncology and Rare Disease gains, and reaffirmed guidance.AZNQ1 2026
- Double-digit revenue and EPS growth in H1 2025, led by Oncology and strong pipeline progress.AZNQ2 2025
- Q1 2025 revenue up 10% at CER, Core EPS up 21%, guidance reaffirmed.AZNQ1 2025
- 2024 revenue up 21% to $54.1bn, core EPS up 19%, with strong growth and robust 2025 outlook.AZNQ4 2024
Next AstraZeneca earnings date
Q3 202630 Oct, 2026
AstraZeneca
Next AstraZeneca earnings date
Q3 202630 Oct, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Anglo-Swedish Pharmaceuticals
AstraZeneca is a multinational biopharmaceutical company established in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. Headquartered in Cambridge, UK, the firm operates globally, specializing in the research, development, manufacturing, and commercialization of prescription medications. It focuses on a range of therapeutic areas including oncology, cardiovascular, renal, metabolism, and respiratory diseases. AstraZeneca's products cater to a diverse set of medical needs and are distributed in numerous countries worldwide. The company is a major player in the global pharmaceutical industry, maintaining a strong commitment to scientific research and the development of new medicines.
A Successful Merger
As previously mentioned, AstraZeneca came to be following the merger of two established pharmaceutical companies. Astra AB, with roots dating back to 1913, had a notable history in pharmaceutical production, introducing various medicines to the market over the decades. Zeneca on the other hand traces its roots back to 1993 after separating from Imperial Chemical Industries. The British half of the modern-day company had a footprint in both therapeutic products and agrochemicals, although it eventually divested from the latter. The merger of these two entities aimed to consolidate resources, streamline research and development processes, and enhance their presence in the global pharmaceutical market. The combined company, now known as AstraZeneca, has since played a significant role in the industry, building upon the foundational knowledge and experience of the two merged parties.
Research and Development
AstraZeneca primarily focuses on the discovery, development, and commercialization of prescription medicines. Their core areas of activity encompass a range of medical conditions, including respiratory, cardiovascular, renal, metabolic, oncology, and autoimmune diseases. The company also engages in significant research and development efforts, with research centers in the UK, Sweden, and the USA. This focus AstraZeneca was one of the pharmaceutical companies heavily involved with the global effort of finding a suitable vaccine during the Covid-19 pandemic. This is an effort they succeeded in, and together with companies like Pfizer and Moderna, they were a key player in the global vaccination effort.
Serving Patients Worldwide
As is common with large pharmaceutical companies, AstraZeneca has a presence in all corners of the world and the company operates in over 100 countries. It has manufacturing and commercial operations distributed across major markets including North America, Europe, Asia, and emerging economies.